Arcus reports casdatifan interim data: 34% ORR in heavily pre-treated ccRCC patients

Arcus Biosciences, Inc.

ORR 34% (11/32) in efficacy-evaluable patients at 100 mg dose; confirmed ORR 25% (8/32).
Disease control rate 81%; median progression-free survival not reached (data cutoff Aug 30, 2024).
Patient population heavily pre-treated: 52% had ≥3 prior lines; 61% intermediate IMDC risk.
Grade 3 TEAEs related to casdatifan were 42% (anemia 36%, hypoxia 9%); no deaths or life-threatening events.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.